HSPA9在肝细胞肝癌的表达和临床意义

Expression and clinical significance of HSPA9 in hepatocellular carcinoma

目的探讨热休克蛋白A9(HSPA9)在肝细胞肝癌中的表达情况及其与临床病理特征和生存预后的关系。方法回顾性分析该院2006年1月至2010年1月外科手术切除治疗49例肝细胞肝癌患者临床及随访资料,免疫组织化学检测上述肝细胞肝癌及癌旁组织中HSPA9的表达情况,统计分析HSPA9表达与临床病理特征及预后的关系。结果肿瘤组织中HSPA9表达较癌旁组织高(t=6.601,P<0.01),并且过表达的HSPA9与淋巴结转移(P=0.005)、TNM分期(P=0.015)、肿瘤分化(P=0.033)、微血管侵犯(P=0.009)及有无复发(P=0.047)密切相关;在生存分析结果中过表达的HSPA9总体生存率更低(P=0.002),术后累计复发率更高(P=0.003);单因素总体生存率和累计复发率分析结果示TNM分期、微血管侵犯、淋巴结转移、肿瘤分化及HSPA9染色可预测患者预后(P<0.05)。结论 HSPA9在肝细胞肝癌中过表达,过表达的HSPA9与侵袭转移病理特征密切相关,并可作为预测肝细胞肝癌的独立预后危险因素。

Objective To investigate the expression of HSPA9 in hepatocellular carcinoma（HCC） and its relationship with clinicopathological features and prognosis. Methods Forty-nine cases HCC treated by operative resection and follow up data in our hospital from January 2006 to January 2010 were retrospectively analyzed. Immunobistochemistry was performed to determine the expression of HSPA9 in HCC and paratumor tissues. The relationship between HSPA9 expression and clinicopathological features and prognosis was statistically analyzed. Results The HSPA9 protein expression in tumor tissue was higher that that in the paratu- mor tissue（t~ 6. 601 ,P^0.01）, moreover the over expression of HSPA9 was significantly correlated with lymph node metastasis （P=0. 005） ,TNM-stage（P=0. 015）, tumor differentiation（P= 0. 033）, microvascular invasion（P= 0. 009） and recurrence（P= 0. 047）. In the survival analysis results, the patients with over expression of HSPA9 had a much lower total survival rate（P= 0. 002）and much higher postoperative cumulative recurrence rate（P=0. 003）. There were significant differences in TNM-stage,mi- crovascular invasion,lymph node metastasis, tumor differentiation and HSPA9 staining for overall survival and cumulative recurrence rate based on a univariate analysis（P〈0.05）. Conclusion HSPA9 has over expression in HCC. The over expression of HS- PA9 is closely related to invasion and metastasis pathological features and can serve as an independent prognostic risk factor for predicting the prognosis of HCC.